Caracterización de pacientes controlados por enfermedad de Basedow Graves en un hospital universitario
Author
dc.contributor.author
Lanas Montecinos, Alejandra
Author
dc.contributor.author
Díaz Amor, Patricia
Author
dc.contributor.author
Eugenin Castillo, Daniela
Author
dc.contributor.author
González Villar, Franco
Author
dc.contributor.author
Cid Ramírez, María Pía
Author
dc.contributor.author
Cordero Anfossi, Francisco
Author
dc.contributor.author
Araya Quintanilla, Verónica
Author
dc.contributor.author
Liberman Guendelman, Claudio
Author
dc.contributor.author
Barberán Manríquez, Marcela
Author
dc.contributor.author
Gac Espinoza, Patricio
Author
dc.contributor.author
Saldías Valenzuela, Neil
Author
dc.contributor.author
Pineda Bravo, Pedro
Admission date
dc.date.accessioned
2018-03-27T21:04:03Z
Available date
dc.date.available
2018-03-27T21:04:03Z
Publication date
dc.date.issued
2017
Cita de ítem
dc.identifier.citation
Rev Med Chile 2017; 145: 436-440
es_ES
Identifier
dc.identifier.other
10.4067/S0034-98872017000400003
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/147030
Abstract
dc.description.abstract
Background: Basedow Graves disease (BGD) is the leading cause of hyperthyroidism. The characteristics of patients seen at a university hospital may differ from those described in the general population. Aim: To describe the clinical features of patients with BGD seen at a university hospital. Material and Methods: Review of medical records of all patients seen at our hospital between 2009 and 2014 with the diagnosis of thyrotoxicosis, hyperthyroidism or BGD. Clinical features, laboratory results and treatments were recorded. Results: We reviewed clinical records of 272 patients; 15 had to be excluded due to incomplete data. BGD was present in 77.9% (n = 212). The mean age of the latter was 42 years (range 10-81) and 76% were women. Ninety six percent were hyperthyroid at diagnosis and thyroid stimulating hormone was below 0.1 mIU/L in all patients. Median free thyroxin and triiodothyronine levels were 3.26 ng/dl and 3.16 ng/ml, respectively. Thyrotropin-receptor antibodies were positive in 98.5% and 85.7% had positive thyroid peroxidase antibodies. Graves orbitopathy (GO) was clinically present in 55% of patients. Of this group, 47% had an active GO, 26% had a moderate to severe disease and 7.8% had sight-threatening GO. As treatment, 26% received radioiodine, 44% anti-thyroid drugs exclusively, 28% underwent thyroidectomy and 2% did not require therapy. Conclusions: In this group of patients, we observed a greater frequency of severe eye disease and a high rate of surgical management. This finding could be explained by referral to highly qualified surgical and ophthalmological teams.